Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019

Demonstration of bioequivalence (BE) is mandatory while developing generic drugs. The scientific concept of BE applies equally to different regulatory agencies. However, the application of the concept may differ for each agency, which can affect the design of BE studies. To evaluate the study practi...

Full description

Bibliographic Details
Main Authors: Ki Young Huh, Eunwoo Kim, Soyoung Lee, Hyounggyoon Yoo, Seonghae Yoon, Kyung-Sang Yu, Jae-Yong Chung
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.651790/full
id doaj-e7d06d1f9b7e47019b476bab57a7d891
record_format Article
spelling doaj-e7d06d1f9b7e47019b476bab57a7d8912021-05-11T14:17:52ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-05-011210.3389/fphar.2021.651790651790Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019Ki Young Huh0Eunwoo Kim1Soyoung Lee2Hyounggyoon Yoo3Seonghae Yoon4Kyung-Sang Yu5Jae-Yong Chung6Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, CHA University School of Medicine, Gyeonggi-do, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Gyeonggi-do, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Gyeonggi-do, South KoreaDemonstration of bioequivalence (BE) is mandatory while developing generic drugs. The scientific concept of BE applies equally to different regulatory agencies. However, the application of the concept may differ for each agency, which can affect the design of BE studies. To evaluate the study practices in terms of the BE concept in South Korea, we retrospectively analyzed BE study reports available from Ministry of Food and Drug Safety between 2013 and 2019. Statistical estimation of the pharmacokinetic parameters, including peak concentration and area under the concentration–time curve to the last measurable concentration, as well as study design, number of subjects in a study, study duration, fasting status, and formulation of specific drugs were obtained. The drugs were classified per World Health Organization Anatomical Therapeutic Chemical Classification and Biopharmaceutics Classification System. Post-hoc intrasubject coefficient of variation and corresponding sample sizes were calculated from the 90% confidence intervals of pharmacokinetic parameters. A total of 143 generic drugs in 588 BE studies were analyzed. The largest number of studies were performed in the area of Cardiovascular system (172 studies), followed by Nervous system (143 studies) and Alimentary tract and metabolism (92 studies). Overall, BE studies in South Korea were conducted in accordance with the global guideline despite the differences in details. BE studies were focused on the several therapeutic areas and conducted in a similar manner. The number of subjects was generally larger than that estimated with 90% power.https://www.frontiersin.org/articles/10.3389/fphar.2021.651790/fullbioequivalenceregulationsgeneric drugIntrasubject coefficient of variationbiopharmaceutics classification system
collection DOAJ
language English
format Article
sources DOAJ
author Ki Young Huh
Eunwoo Kim
Soyoung Lee
Hyounggyoon Yoo
Seonghae Yoon
Kyung-Sang Yu
Jae-Yong Chung
spellingShingle Ki Young Huh
Eunwoo Kim
Soyoung Lee
Hyounggyoon Yoo
Seonghae Yoon
Kyung-Sang Yu
Jae-Yong Chung
Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
Frontiers in Pharmacology
bioequivalence
regulations
generic drug
Intrasubject coefficient of variation
biopharmaceutics classification system
author_facet Ki Young Huh
Eunwoo Kim
Soyoung Lee
Hyounggyoon Yoo
Seonghae Yoon
Kyung-Sang Yu
Jae-Yong Chung
author_sort Ki Young Huh
title Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
title_short Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
title_full Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
title_fullStr Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
title_full_unstemmed Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
title_sort current bioequivalence study designs in south korea: a comprehensive analysis of bioequivalence study reports between 2013 and 2019
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-05-01
description Demonstration of bioequivalence (BE) is mandatory while developing generic drugs. The scientific concept of BE applies equally to different regulatory agencies. However, the application of the concept may differ for each agency, which can affect the design of BE studies. To evaluate the study practices in terms of the BE concept in South Korea, we retrospectively analyzed BE study reports available from Ministry of Food and Drug Safety between 2013 and 2019. Statistical estimation of the pharmacokinetic parameters, including peak concentration and area under the concentration–time curve to the last measurable concentration, as well as study design, number of subjects in a study, study duration, fasting status, and formulation of specific drugs were obtained. The drugs were classified per World Health Organization Anatomical Therapeutic Chemical Classification and Biopharmaceutics Classification System. Post-hoc intrasubject coefficient of variation and corresponding sample sizes were calculated from the 90% confidence intervals of pharmacokinetic parameters. A total of 143 generic drugs in 588 BE studies were analyzed. The largest number of studies were performed in the area of Cardiovascular system (172 studies), followed by Nervous system (143 studies) and Alimentary tract and metabolism (92 studies). Overall, BE studies in South Korea were conducted in accordance with the global guideline despite the differences in details. BE studies were focused on the several therapeutic areas and conducted in a similar manner. The number of subjects was generally larger than that estimated with 90% power.
topic bioequivalence
regulations
generic drug
Intrasubject coefficient of variation
biopharmaceutics classification system
url https://www.frontiersin.org/articles/10.3389/fphar.2021.651790/full
work_keys_str_mv AT kiyounghuh currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019
AT eunwookim currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019
AT soyounglee currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019
AT hyounggyoonyoo currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019
AT seonghaeyoon currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019
AT kyungsangyu currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019
AT jaeyongchung currentbioequivalencestudydesignsinsouthkoreaacomprehensiveanalysisofbioequivalencestudyreportsbetween2013and2019
_version_ 1721444177351278592